Here is a summary report of the recent earnings conference call transcripts focusing on key financial metrics:

- Total fourth-quarter revenues were $3.2 billion, growing by 4.4% on a comparable currency-neutral basis. The full-year revenues were $12.1 billion, growing by 4.5%, in line with previously communicated expectations.

- The adjusted EPS growth was 13.2% in both the fourth quarter and the full year, reflecting the ability to overcome the dilution from the Respiratory divestiture and the U.S. dispensing change.

- The company significantly expanded its margins and captured an additional $80 million in annualized synergy cost savings related to CareFusion, reaching $250 million in annualized cost savings on a cumulative basis through the end of fiscal 2017.

- The company is on track to achieve approximately $350 million in total annualized cost synergies by the end of fiscal 2018, which is the high end of the previously communicated range.

- The revenue growth by segment on a comparable currency-neutral basis included growth of 3.9% for BD Medical, 1.5% for Medication and Procedural Solutions (MPS), 6.7% for Medication Management Solutions (MMS), 6.4% for Diabetes Care, 3.4% for Pharmaceutical Systems, 5.4% for BD Life Sciences, and 5.2% for Diagnostic Systems.

- Developed markets revenues were strong, growing by 3.4% for the full fiscal year, while emerging markets revenue grew by a strong 12.7% in the fourth quarter and 10.1% for the full year, exceeding expectations.

- Fourth quarter currency-neutral sales in global safety increased by 3.9% year-over-year, with international sales growing by 9.1% currency neutral and sales in emerging markets growing by 16%.

- The company expects revenue growth of 4% to 5% on a currency-neutral basis for the full fiscal year 2018, with EPS growth of 15% to 16% on an underlying basis.

- The gross profit margin is expected to be between 54% and 55%, SSG&A as a percentage of sales between 23% and 24%, R&D investment in line with fiscal year 2017 at 6% to 7% of revenues, and the operating margin to improve to between 24% and 25% of revenues.

- The company expects an increase in its effective tax rate for fiscal year 2018, resulting in a tax rate between 17% and 19%, and anticipates an adjusted average fully-diluted share count to be approximately 219 million shares.

In conclusion, the company is confident in its ability to deliver another strong year of performance in fiscal year 2018 and is looking forward to the closing of the Bard acquisition, which is expected to create an even more powerful healthcare company. The company's financial parameters related to the Bard transaction are consistent with what was previously announced, and it expects low-single-digit per share accretion. The company also anticipates strong cash flow and continued momentum in the coming year.